A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.

[1]  R. Getzenberg,et al.  Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. , 2005, The Journal of urology.

[2]  G. Joyce,et al.  Economic costs of benign prostatic hyperplasia in the private sector. , 2005, The Journal of urology.

[3]  S. Madersbacher,et al.  Benign prostatic hyperplasia: age-related tissue-remodeling , 2005, Experimental Gerontology.

[4]  Qing Yang,et al.  Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival , 2005, Cancer Cell International.

[5]  R. Dhir,et al.  Androgen regulation of JM-27 is associated with the diseased prostate. , 2004, Journal of andrology.

[6]  Leonard S Marks,et al.  Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. , 2003, Clinical chemistry.

[7]  M. Thiyagarajan.  α-Adrenoceptor Antagonists in the Treatment of Benign Prostate Hyperplasia , 2002, Pharmacology.

[8]  R. Dhir,et al.  Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Michelotti,et al.  α1‐Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1d subtype in filling symptoms and effects of ageing on vascular expression , 2000, BJU international.

[10]  R. Levin,et al.  Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. , 2000, The Journal of urology.

[11]  J. Oesterling,et al.  Benign prostatic hyperplasia: A review of its histogenesis and natural history , 1996, The Prostate. Supplement.

[12]  A. Wein,et al.  Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder , 1990, The Prostate. Supplement.